Preclinical Perspectives on Platinum Resistance
- 1 January 2000
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 59 (Supplement), 1-8
- https://doi.org/10.2165/00003495-200059004-00001
Abstract
In the 30 years since the introduction of cisplatin into the clinic, laboratory studies have provided considerable information as to both how the drug exerts its antitumour effects and how some...Keywords
This publication has 41 references indexed in Scilit:
- GemcitabineDrugs, 1997
- Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panelBiochemical Pharmacology, 1996
- DNA Repair: Enzymatic Mechanisms and Relevance to Drug ResponseJNCI Journal of the National Cancer Institute, 1996
- Solution Structure of a Cisplatin-Induced DNA Interstrand Cross-LinkScience, 1995
- Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatinNature, 1995
- ERCC1 and ERCC2 Expression in Malignant Tissues From Ovarian Cancer PatientsJNCI Journal of the National Cancer Institute, 1992
- Overexpression of Metallothionein Confers Resistance to Anticancer DrugsScience, 1988
- Interaction of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathioneBiochemistry, 1987
- Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitationBiochemistry, 1985
- Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteusMutation Research, 1978